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Abstract
The pharmacokinetics of 80 mg frusemide given orally were investigated in normal subjects using a direct 
HPLC method for parent drug and its acyl glucuronide conjugate.
Two half-lives could be distinguished in the plasma elimination of both frusemide and its conjugate, 
with values of 1-25±0-75 and 30-4zb 11*5h for frusemide and 1-31 ±0*60 and 33*2±28*0h for the 
conjugate. The renal excretion rate-time profile showed two phases; the rapid elimination phase lasted 
from 0-15 h and the second and slow phase, from 15-96 h. During the first 15 h, 33 '3 ±  4*8% of the dosed 
frusemide was excreted; in the remaining period 15-96 h, 4'6 ±  1 *5% was excreted. In the same two periods 
the excretion of the glucuronide was 13*4 ±4*7 and 1*9 ±  1*1%, respectively. The mean renal clearance of 
frusemide was 90-2±  16’9 mLmin-1 during the first period and 91*5 ± 29*3mLmin“1 in the remaining 
period, during which the stimulation of urine production was absent. The renal clearance of the acyl 
glucuronide was 702 db 221 mLmin”1 in the first period, but only 109 ±  51 *0 mLmin“1 in the second period. 
The stimulated urine production in the first 6h after administration amounted to 2260 ±  755 mL 
(measured urine production minus baseline value of I mLmin-1 (360 mL). During the second or rebound 
period (6-96 h after drug administration), the quantity of urine was 990 ±  294 mL lower than what would 
lave been expected from the baseline production of 5400 mL, This reduced production (0-82m Lm in"1) is 
equivalent to an 18% reduction in the average urine flow rate of 1 mLmin-1.
Frusemide (4-chloro-Af-(2“furylmethyl)-5-sulphamoylan-
thranilic acid, pKa 3*9) inhibits the active reabsorption of 
chloride ions in the thick ascending limb of the loop of 
líenle by binding to one of the Cl- binding sites of the NaH / 
2C1“/K+ co-transport system. In man, frusemide is meta­
bolized to its acyl glucuronide (Beerman et al 1975, 1977). 
Acyl glucuronides are unstable in alkaline media (pH > 7*0); 
therefore, for analysis urine must be kept acidic at pH 5*0 in 
order to prevent hydrolysis and isomerization of acyl glu­
curonides even before excretion (Faed 1984; Rachmel et ai 
1985; Vree et al 1992a, 1993a, b).
The reported half-lives (ti) of frusemide and its glucur- 
onide are of the order of 2h (Hammarlund et al 1985; Vree 
et al 1994, 1995b). In a pilot experiment in our laboratory, a 
second, long half-life of frusemide and its acyl glucuronide 
became visible (Vree et al 1994).
Hammarlund et al (1985) mentioned the effect of an acute 
tolerance to frusemide’s effect as being a homeostatic adap­
tive response to the acute loss of salt or water. This homeo­
static response, which Reyes called a rebound effect (Reyes 
1991), may also be the result of a prolonged disposition of 
frusemide at the Cl- binding sites.
The aim of this investigation was to study the pharmaco­
kinetics of frusemide and its acyl glucuronide in healthy 
volunteers, to assess the long half-life of parent drug and 
glucuronide conjugate, and to analyse the diuretic and 
antidiuretic response.
Correspondence: T. B. Vree, Department of Clinical Pharmacy, 
Academic Hospital Nijmegen Sint Radbóud, Geert Grooteplein 
Zuid 8, 6525 GA Nijmegen, The Netherlands.
Materials and Methods
Drugs and chemicals
Frusemide and Lasix (40 mg tablets) were obtained from 
Hoechst (Amsterdam, Netherlands and Frankfurt, Ger­
many). All other reagents were of analytical grade and 
obtained from Merck (Darmstadt, Germany).
Frusemide acyl glucuronide was isolated and identified in 
human urine after administration of 80 mg frusemide (Vree 
et al 1994).
Subjects
Seven human subjects (4 males (non-smokers), 3 females 
(one smoker), mean age 34 ± 7  years, mean bodyweight 
80 ± 6  kg) participated in the study. The volunteers took 
80 mg frusemide orally (as Lasix) after an overnight fast. 
The study had the approval of the hospital ethics committee, 
and informed consent was obtained from the volunteers.
Sampling
Fingertip blood samples (2mL), obtained with Monolet 
lancets (Monoject, St Louis, USA), were collected in hepar- 
inized Eppendorf vials (2 mL) at regular time intervals during 
72 h following drug administration. After centrifugation, 
plasma samples were stored at -20°C pending analysis.
Urine was collected upon untimed voiding. The total time 
of sample collection was 96 h. Urinary pH was kept acidic 
(pH 5*0-5-5) by the oral intake of 1 g ammonium chloride 
four times per day (Ammonchlor, Siidmedica, Munich, 
Germany). Four urine samples of 5mL from each void
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were immediately stored at -20"C pending analysis. Total 
sampling time of urine was 96 h.
Each urine void (200-400 mL) was followed by ingestion 
of 100 mL water during the first period of 6h.
Drug analysis
Frusemide and its acyl glucuronide were assayed by HPLC 
as reported elsewhere (Vree et al 1994). The limit of quanti­
tation of frusemide in plasma was 7 ngm L“1, and for the 
glucuronide 10 ngm L-'1. The limits of quantitation in urine 
were 100 and 150 ngm L 1 for the parent drug and glucur- 
onide, respectively.
The intra- and interday variation of frusemide and 
glucuronide in plasma and urine was <5% . Recovery of 
frusemide after deproteinization of plasma was 91*5 ±  5-1 %, 
and that of the glucuronide was 85'5d:4*7%.
Plasma samples (100 /¿L) were deproteinized with 100 \CL 
acetonitrile and centrifuged at 3000#; 20 /¿L of the super­
natant was injected onto the column. The plasma samples 
were immediately injected onto the column. A stability test 
has shown that the glucuronide was stable at pH 7*4 for only 
30 min.
Urine samples were diluted with an equal volume of 
water, and 20/¿L of that mixture was injected onto the 
column. The sample tray of the autosampler was protected 
from light.
Plasma binding
The in-vivo protein binding of frusemide and glucuronide 
was measured in volunteer plasma samples by means of the
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F ig. 1. Plasma concentration-time curve and renal excretion rate- 
time profile of frusemide and frusemide acyl glucuronide in a 
representative volunteer after an oral dose of 80 mg frusemide. 
The long i\ti is visible in both the plasma and the urine curve.
Amicon Micropartition system MPS-1 (Grace BV, Amico 
Division, Capelle aan de IJssel, The Netherlands). The 
average protein binding ( i s .d .)  was calculated from two 
plasma samples from each volunteer obtained at maximal 
plasma concentration, 1-2 h after administration. No aspe- 
ciiic drug binding to the filters was observed.
Data analysis
Curve fitting was carried out (r2 >0*97), and the pharma­
cokinetic parameters of the plasma concentration-time 
curves, renal excretion rate-time profiles, and urine flow­
time profiles were calculated using the MediWare computer 
program (Proost & Meyer 1992). Areas under the concen­
tration-time curves (AUC) were determined by the linear 
trapezoidal rule. Oral clearance (CL0) and mean residence 
time (MRT) were calculated by standard methods (Proost & 
Meyer 1992).
The renal clearance during the appropriate period was 
calculated by dividing the amount excreted in the urine 
during this period by the corresponding AUC value. Non- 
renal clearance was defined as the oral clearance minns the 
renal clearance.
Recovery-, or rebound-time of the urine flow was defined 
as the time elapsed between the end of the urine flow 
stimulation at which the urine flow was < 1 m Lm in^1 and 
the time at which the urine flow reached again the value of 
> 1 mLmin“ 1.
Analysis of variance was carried out by standard proce­
dures, and statistical difference was defined at P<0-05.
Results
Fig. I shows the plasma concentration-time curves and renal 
excretion rate-time profiles of frusemide and its acyl glucur­
onide in one representative subject, in which the slow 
elimination phase is visible in both the plasma and urine 
curves.
Table I summarizes pharmacokinetic parameters of fru­
semide in plasma and Table 2, the parameters in urine,
Frusemide is quickly absorbed as can be concluded from 
the small values of tj8g, tmax, and t xA  of absorption. The lag 
time in blood for frusemide is 0-29 ±  0* 16 h and of frusemide 
acyl glucuronide 0*32 ±0-24 h, (P=1*0). Both compounds 
were also quickly excreted; the t[ag of the compounds in 
urine do not differ significantly and did not differ from those 
in plasma.
Two half-lives (a and ¡3) can be distinguished , in the 
plasma elimination of both frusemide and its conjugate. 
The t{a values of frusemide and its acyl glucuronide were 
1 *25 =b0*75 and 1*31 ± 0 -6 0 h, respectively, which are not
significantly different.
The plasma concentration- and renal excretion rate-time 
curves run parallel, resulting in similar values of the calcu­
lated pharmacokinetic parameters; plasma and urine t^  
values of frusemide are respectively 33-2±28-0 and 
29-7 ± 21*9 h. The corresponding values for frusemide acyl 
glucuronide are 30*4i  11‘5 and 29*9 ± 2 0 ’2h.
Although the long elimination half-life of frusemide and 
its acyl glucuronide in plasma was visible in five out of the 
seven volunteers, it was clearly visible in the urinary excre­
tion curves of all volunteers (29*7 ±  21‘9 h, CV =  73*7%).
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Table 1. Pharmacokinetic parameters in plasma of frusemide (80 mg) 
(n =  7).
Parameter Frusemide Acyl glucuronide P
F 0*53 ±0*07 0*15±0’04 0*0003
tlag (h)
C  (h)
0-29 ±0*16 0*32 ±0-24 >0*80
1*98 ±0-98 1-50 ±0-74 0*58
U I sI ä  v  /
Cmnx ((j,gmL~[) 2*20 ±0*84 0*11 ±0*07 0*0156
I 1 J H s \  > 1  W  *
tbs (h) 
l!a (h)
0*30 ±0*26 0*68 ±0*50 0*034
1-*25 ±0*75 1*31 ±0*60 0*47
+ I X  \  /
% (h)
MRT ih)
33*2 ±28*0 30*4 ±11*5 1*00
10-2 ± 11-6 14*8 ±15*9 0*81
CL0 (mLrnin-1) 131 ±26-5
CLr (mLmin-1)1 \  M W
0-15 h 90*2 ±16-9 702 ±221
15-96 h 91*5 ±29*3 109 ±51-0
CLnr (mLmin !)
0 -1 5 h 41*0± 16*5
15-96 h 32*1 ±19*6
VdM (L) 21-9 ±  12*3 94*8 ±68*9 0-0013
Excreted (% dose)
0-15 h 33*3 ±4*8 13*4 ±  4*7 < 0-0001
1 5 -9 6 h 4*6 ±  1*5 1*9 ±  1*1 < 0*0001
Protein binding (%) 98*0 ±2*0 96*1 ±2*0 0*0284
P difference between frusemide and its acyl glucuronide.
The large coefficient of variation was caused by two 
volunteers showing extremely long half-lives of 37*8 h and 
73-7 h (mean 55*8 ±  25*4 h; CV =  45.5%). The other five
volunteers showed a much more consistent half-life of
16*4rL 1 *94h (11-8%).
For frusemide acyl glucuronide the mean half-life in urine 
was 29*9 ±  20*2h (67*6%). The great variation was caused 
by three volunteers showing long half-lives of 37*8, 54*4, and 
58*6h (50*3±11*0h; 21*9%). The other four volunteers 
showed a relatively short half-life of 14*6 ±  2-63 h (18-0%).
Protein binding
The protein binding of frusemide (98-0 ±2*0%) is signifi­
cantly higher than that of the acyl glucuronide (96* 1 ±  2*0%, 
P  =  0*0284).
Percentage o f the dose excreted in the urine
The main compound in the urine was frusemide. The renal
excretion rate-time profile showed two phases, the rapid 
elimination phase lasting from 0-15h, and the second, slow 
phase from 15-96 h,
During the first 15 h, frusemide excreted accounted for 
33*3 ±4*8% of the dose; in the remaining 15-96-h period, 
4*6 ±1*5% was excreted. In the same two periods, the 
percentage frusemide acyl glucuronide excreted was 
13*4±4*7%, and 1*9±1*1%, respectively. In total, 
46*7 ±  8*3% was excreted during the first 15h, and 
6-4 ±2*1% during the remaining 15-96-h period. During 
the entire period (96 h), 53*0 ±7*2% of the dose was recov­
ered from the urine.
Renal clearance
The mean renal clearance of frusemide was calculated for 
the two elimination phases and was found to be 
90*2± 16*9mLmin~l during the first period (0-15h), and 
91*5±29*3mLmin~t during the remaining 15—96 h period,
Table 2. Pharmacokinetic parameters in urine of frusemide (80 mg) (n ~  7).
Parameter Frusemide Acyl glucuronide P
tb* (h) 0*20 ±0-17 0*42 ±  0*24 0*068
(h) 0*86 ±0*51 1*19 ±  0*44 0*24
Umax Qig min"1) 177 ±34*0 92*6 ±36*5 0*0007
a^bs (h) 0*32 ±0*34 0*37 ±0*42 0*80
(h) 1 *23 ±  0*47 1 *45 ±  0*51 0*35
%  (h) 29*7 ±  21 *9 29*9 ±20*2 > 0*8
MRT (h) 11*1 ±10*4 11 *7 ±7*9 > 0*8
Excreted (%)
0-15 h 33*3 ±4*8 13*4 ±  4*7 < 0*0001
15-96 h 4*6 ±  1*5 1 *9 ±  M 0*0018
Total excreted (%)
• <
0-15 h 46*7 ±8*3
1 5 -9 6 h 6*4 ±2*1 0*0001*
0-96 h 53*0 ±7*2 0*15**
P  difference between frusemide and glucuronide; *between 0 -1 5 h  and
15-96 h; **between 0-15h  and 0-96h. *Change between initial and final 
elimination in the urine profile.
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Table 3. Mean urinary diuresis parameters o f  frusemide (80 mg) 
(n =  7).
Parameter Mean ±  s.d. P
Diuresis
tiag (h) 0*18 ±  0T9
U *  (h) 0-77 ± 0 5 2
U max (mLmin-1) 21*3 ±  6*1
ti (h) 0-76 ±0*26
M RT (h) 2*59 ±0-82
telïect (h) 5*5 ±0-5
 ^re bound (h) 64-7 ±  14-4
Urine production (mL)*
0 -6  h + 2260*0 ±  755 0-0014**
6-96  h -990*0 ± 2 9 4
*Urine production exceeding the baseline value of 1 raLmin"1. 
**P value, difference between the two periods of urine produc­
tion. teff?ct, trcbound, time course of the effect. U mnx maximal urine 
production.
in which there was no stimulation of urine production. The 
clearance values in both periods were similar (P>  0*8) 
(Table 1).
The renal clearance of the acyl glucuronide was 702 ±  
221 mLmin-1 in the first period but significantly decreased 
to 109 ±  51*0 mLmin-1 in the second period (P = 0*0083).
Urine production
The stimulated urine production in the first 6 h after admin­
istration amounted to 2260 ±  155 mL (measured urine pro­
duction minus baseline value of 1 mLmin”1 (360mL) 
(Table 3).
During the second or rebound period of 6-96 h after drug 
administration the average urine production was 
990±294m L lower than what would have been expected 
from the baseline production of 5400 mL. This reduced 
production is equivalent to an 18% reduction in the baseline 
urine flow rate of 1 m Lm in"1 (0*82 mLmin-1).
The recovery- or rebound-time of the urine flow lasted 
64-7 ±  14*4 h (CV =  22*3%).
Table 4 compares the plasma concentration and renal 
excretion rates of frusemide and its glucuronide at the onset 
and end of stimulation of the urine production.
Discussion
P harm acokinetics
This study shows that frusemide and its acyl glucuronide
exhibit two half-lives. The short half-life of approximately 
2 h is well known and related to the pharmacodynamic effect 
of the stimulation of the overall urine production. The 
second half-life of approximately 20-30 h has not been 
reported previously. During this slow elimination phase, 
only 4*6 ±  1-5% of the administered dose is excreted, which 
is 14% of the amount excreted during the first 15 h.
During the first phase, 13*4% of the acyl conjugate is 
excreted, and during the second phase, only 1*9 ±1*1%, 
which is 14% of the first phase and the same percentage 
reported for frusemide.
The short t}a values of frusemide and its acy! glucuronide 
in plasma give rise to the assumption that both compounds 
are excreted by glomerular secretion plus active tubular 
secretion. Indeed, the apparent renal clearance of frusemide 
was 90mLmin“1, which is similar during the first and 
second phases of elimination.
The apparent renal clearance value of the acyl 
glucuronide is high during the first phase (0-6 h; 702 ±  
221 m Lm in-1) and lower in the second phase (109 ±  
51*0m Lm in"1). In the second phase, the renal clearance 
values of frusemide and its acyl glucuronide are similar. The 
extreme high renal clearance of the acyl glucuronide during 
the first phase may be the result of hepatic and renal 
formation of the glucuronide (Smith & Benet 1983; Vree 
et al 1992a, b); the latter ceased in the second phase of the 
elimination. Probenecid inhibits the renal clearance of both 
frusemide (Chennavasin et al 1979; Smith et al 1980; Vree et 
al 1995b) and its acyl glucuronide (Vree et al 1995b).
The relation between stimulation of the urine production 
and the renal formation of the acyl glucuronide may be 
coincidental, or it may indicate that the pharmacodynamic 
effect is the result of the action of the renal acyl glucuronide.
Onset and offset o f  the effect
The pharmacodynamic activity of frusemide is believed to 
be produced as follows. The compound passes the kidney (in 
the thick ascending part of Henle’s loop), until its concen­
tration or excretion rate reaches 21 ^gm in-1 (Koajarern et 
al 1982); the reabsorption of the Cl" ions is inhibited, 
resulting in a decrease in water reabsorption and increase 
in overall urine flow.
Indeed, as soon as frusemide and its acyl glucuronide 
appear in the urine after a similar lag time, the urine flow 
increases.
Table 4 shows that in our group of subjects, a frusemide 
renal excretion rate of 28*0 ±  2*9 (Mg min-1 (10*4 %CV) in the
Table 4. Comparison of the urine flows, plasma concentrations, and renal 
excretion rates of frusemide and frusemide acyl glucuronide at the onset and end 
of the effect (mean ±  s.d.) (n =  7).
Parameter
Urine flow (mLmin-1) 
Plasma
Frusemide (¿¿gmL-1)
Acyl glucuronide (/ig mL“1 )
Urine
Frusemide (fig min-1)
Acyl glucuronide (¿igmin-1)
Start/onset End
8*04 ±4*60 1-81 ±0*47 0-0010
1*06±0*45 0*44 ± 0 T  7 0-0014
0*059 ±0*062 0*046 ±0*020 0-55
62*9 ±58*1 28*0 ±2*9 0*0930
14*9 ±  14*2 19*0 ±  10*8 0*5039
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elimination phase of the kinetic curve is correlated with the 
end of the stimulation of the urine production. The corre­
sponding excretion rate of the acyl glucuronide is 
19-0 ±  10*8/¿gmin“1 (CV^56*8%). During the onset of 
the pharmacodynamic effect, the processes occur much 
faster, producing a larger coefficient of variation. For the 
first urine sample, the average urine production is already 
8-0 ±4-6 mLmin"1 (57*5%) with a frusemide excretion rate 
of 62-9±58-l pgmin-1 (92-6%) and an acyl glucuronide 
value of 14*9± 14*2//gmin”1 (94*8%). Strikingly, the phar­
macodynamic effect starts and ends with excretion rates for 
the acyl glucuronide that do not differ (P =  0*50). The large 
difference and coefficients of variation of the excretion rates 
of frusemide in the first urine sample and onset of the 
pharmacodynamic effect makes the difference between 
onset and end of effect not statistically different.
Similar data can be derived for the plasma concentration 
of parent compound and metabolite and the start and end of 
the urine flow stimulation (Table 4).
A great difference is observed between frusemide plasma 
concentration at onset and end of the urine flow stimulation 
(P — 0.0014). This is not observed for the frusemide acyl 
glucuronide for which the concentrations are not signifi­
cantly different (P =  0.55).
The stimulation of the urine production faded 
(< 1 mLmin“1) when the renal excretion rate of frusemide 
drops below the threshold of 20 ¿¿gmin“1, as reported by 
Koajarern et al (1982). During the absorption phase, this 
value was already achieved in the second urine sample 
within 1 h of oral administration. The onset looks like an 
instantaneous maximum effect for an 80-mg dose.
Rebound
The pharmacodynamic effect-time curve shows a biphasic 
character. First, there is binding to one of the Cl~ binding 
sites of the Na+/2C1”/K+ co-transport system of the thick 
ascending part of the loop of Henle, resulting in an increase 
of the urine production greater than 1 mLmin“1 (Greger & 
Schlatter 1983; Wittner et al 1991; Swan 1994), A rebound 
phase follows in which the urine production is less than the 
baseline value of 1 mLmin"1.
During the pharmacodynamic effect, 2260 ±  755 mL was 
excreted above the baseline value of 1 mLmin“1 for the 
unmedicated and well-hydrated subjects. Despite the fact 
that the subjects maintained their normal drinking and 
eating patterns, during this excess urine excretion period, 
it took three days for the body to regain this amount of fluid. 
The average urine production over those three days was 
990 ±  294 mL less than what would have been excreted with 
the baseline value of 1 mLmin”1.
The baseline urine production of 1 mLmin“1 (=  1440mL 
in 24) was taken as a conservative estimate; the subjects 
showed values of 1 -2 mLmin”1 in other long-lasting phar­
macokinetic experiments with naproxen (Vree et al 1993a, b) 
and sulphamethoxazole (Vree et al 1995a).
This time course of the rebound effect was subjectively felt 
to be three days, as experienced by the same subjects in 
other, short-term, frusemide experiments (Vree et al 1995b). 
Therefore, the urine production was measured for four days 
in order to find an empiric measure for the restoration of the 
baseline value. The recovery time was found to be 65 h, and
the total time of urine flow stimulation plus recovery time 
was 6h + 65 h =  71 h (3 days). The reported 24-h recovery 
period reported by Reyes (1991) was based on a collection
period of only 24 h.
During this recovery period, frusemide and its acyl glu­
curonide were slowly eliminated from the body with a long 
half-life of 20-30 h for this phase. This recovery period was 
named acute tolerance to frusemide diuresis in man (Ham- 
marlund et al 1985); rebound effects were named by Reyes 
(1991). This recovery or rebound period coincides with the 
t^  of 20-30 h for both frusemide and its acyl glucuronide.
The rebound effect may be the result of a biphasic effect of 
frusemide or its acyl glucuronide. In concentrations or renal 
excretion rates > 20 ¿¿gmL”1, there is a stimulation of the 
urine production, while at concentrations below this thresh­
old there exists an inhibition of the urine production. These 
low renal excretion rates may exist in the slow elimination 
phase after administration of a therapeutic dose of 40- 
80 mg or higher dose, or they can be obtained after admin­
istration of 5 mg frusemide four times a day. The urine 
production under this low frusemide dosing regimen should 
be compared with baseline values of urine production in 
each patient or volunteer. When this was carried out in a 
pilot experiment, no inhibition of urine production was 
detected.
Clinical impliedtions
Cumulation of the frusemide plasma concentrations, due to 
the slow elimination phase, and cumulation of the rebound 
or recovery phase may induce a braking of the therapeutic 
or pharmacodynamic effect (Brater 1991),
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